Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Largest Clinical Study of Parkinson’s Disease Reaches 10,000-Patient Milestone, Reveals Critical Learnings

NEW YORK & MIAMI - January 10, 2018 - The Parkinson’s Foundation today announced the enrollment of the 10,000th Parkinson’s patient and the discovery of critical new learnings in what represents the largest clinical study of Parkinson’s disease in history. Launched in 2009, the study has grown from a small pilot to 29 expert clinics in five countries and serves as a platform for clinical studies to improve the lives of everyone with Parkinson’s. 

Specifically, the “Parkinson’s Outcomes Project” evaluates the complete range of factors associated with Parkinson’s disease: medications and other treatments, motor symptoms, cognition, anxiety A feeling of nervousness, worried thoughts and physical distress. and depression, and caregiver burden. The study, which includes more than 100 people who have lived with Parkinson’s for more than 30 years and 83 people diagnosed before they were 30 years of age, covers more than 25,000 clinical visits and input from almost 9,000 family care partners. Critical discoveries from the study include:

  • Regular neurologist care, which could save the lives of thousands of people every year, should be better prioritized by Parkinson’s patients and caregivers
  • Greater attention should be paid to physical activity, as increasing exercise and general movement to at least two-and-a-half hours a week slows the decline in quality of life
  • Mental health should be better prioritized, as depression and anxiety are leading factors determining the overall health status of patients
  • Gender differences from informal family caregivers for women with Parkinson’s is putting them at a disadvantage, and greater awareness is needed. Women with Parkinson’s are more likely to have a paid caregiver than men at the same stage, unlike men who are more likely to rely on their spouses and family members for support with everything from daily care to doctor visits

“When the foundation launched the Parkinson’s Outcomes Project nine years ago, our goal was to understand the impact of Parkinson’s on everyone living with the disease. We have obtained a wealth of information in what now represents the broadest and most inclusive patient population ever assembled in a clinical study of Parkinson’s,” said Peter Schmidt, PhD, Senior Vice President, Chief Research and Clinical Officer of the Parkinson’s Foundation, who leads the study. “The data we are collecting is informing trials to deliver new and better therapies.”

Added Thomas Davis, MD, Director of Movement Disorders at Vanderbilt University, study co-chair: “This project is truly innovative in that it not only follows thousands of patients over time, but that it studies everyone with Parkinson’s, from the newly diagnosed to people who have lived with the disease for 30 years or more. We’re working to ensure that every patient receives the best possible care, no matter where they’re seen.”

The Parkinson’s Foundation partners with its vast network of Centers of Excellence, leading academic and medical institutions around the world, to determine which Parkinson’s care teams achieve the best results and why. The network is comprised of 42 medical centers that deliver care to more than 100,000 people with Parkinson’s every year. Parkinson’s Foundation Center of Excellence status is the most respected and sought-after designation in the field of Movement Disorders, with each center required to meet rigorous clinical, research, professional education and patient service criteria.

“We are studying the quality of Parkinson’s care delivered at our Centers of Excellence to help patients who aren’t being seen at one,” said Fernando Cubillos, MD, who oversees operations for the Parkinson’s Outcomes Project. “Our goal is to help identify the best care and disseminate that information widely.”

The Parkinson’s Outcomes Project is led by a steering committee with members from each participating clinic and rotating co-chairs. The current co-chairs are: Kelly Lyons, PhD, Kansas Medical Center; Thomas Davis, MD, Vanderbilt University Medical Center; and Adolfo Ramirez-Zamora, MD, University of Florida. Gene Nelson, DSc, from the Dartmouth Institute for Health Policy & Clinical Practice, serves as advisor on quality programs. 

For more information about the study, visit www.parkinson.org/outcomes.

About the Parkinson’s Foundation 
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease 
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Wednesday, January 10, 2018
Afghanistan Veteran, PDF Champion to Complete Luxembourg IRONMAN for Parkinson’s Research on Saturday, June 20
Friday, May 29, 2015

US Army First Lieutenant Ashley Murray, a Piscataway, NJ, native, is running, biking and swimming to fight for a future without Parkinson’s disease. First Lt. Murray, an Afghanistan veteran who is currently stationed in Germany, will complete the Ergo IRONMAN 70.3 Luxembourg triathlon on Saturday, June 20 to raise funds for the Parkinson’s Disease Foundation (PDF).

Bal du Printemps Honors Supporters, Raises $460,000 for Research
Thursday, May 21, 2015

One hundred and seventy-five guests attended the annual Bal du Printemps Galapresented by the Parkinson’s Disease Foundation (PDF) at The Metropolitan Club in New York City on Tuesday, May 19, 2015 for an intimate and important evening.Willie Geist, co-anchor of NBC News’ “Today” and co-host of MSNBC’s “Morning Joe,” served as the Master of Ceremonies for the evening.

Parkinson’s Disease Foundation Announces New Members of People with Parkinson’s Advisory Council
Tuesday, May 12, 2015

The Parkinson’s Disease Foundation® (PDF®) is pleased to announce new members of its People with Parkinson’s Advisory Council. The council is made up of people living with Parkinson’s disease and care partners who help drive PDF’s goals of ending the disease and supporting those affected by it.

The National Parkinson Foundation Welcomes Two New Board Members
Monday, April 6, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Gregory E. Katz and Jonathan Levin.

Rasheda Ali Joins Moving Day® Tampa
Monday, March 16, 2015

Rasheda Ali Joins Tampa Bay Residents to Get "Moving" for Parkinson's Disease

The National Parkinson Foundation Invests in the Future of Parkinson's Research
Monday, March 2, 2015

Support Provided for the Next Generation of Movement Disorder Neurologists

The National Parkinson Foundation Welcomes New Board Member
Wednesday, February 18, 2015

MIAMI, FL — The National Parkinson Foundation (NPF) announced the election of Ricardo Caporal to its Board of Directors. 

National Parkinson Foundation Expands Expert Care Network
Wednesday, February 11, 2015

UC San Diego Health System Designated Center of Excellence 

Erin Borger and Paul Blom Join NPF's Board of Directors
Tuesday, January 13, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Erin R. Borger and Paul R. Blom. 

FDA Approves Revolutionary Parkinson's Treatment and NPF Is Helping Deliver it to You
Monday, January 12, 2015

The National Parkinson Foundation (NPF) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.